BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld Asia
Home
» Hutchison's Epitinib passes BBB in lung cancer patients who have brain tumors
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hutchison's Epitinib passes BBB in lung cancer patients who have brain tumors
Dec. 14, 2016
By
Shannon Ellis
No Comments
SHANGHAI – Shanghai-based Hutchison Medipharma Co. Ltd. presented phase I data for epitinib at the World Conference on Lung Cancer in Vienna showing that epitinib is a safe EGFR inhibitor with the ability to cross the blood-brain barrier (BBB).
BioWorld Asia